Safety and long-term improvement of mesenchymal stromal cell infusion in critically COVID-19 patients: a randomized clinical trial

Table 3 Survival status of COVID‐19 patients

Patient	Interval between first cell infusion and death (days)	Study group	Oxygenation PaO₂/FiO₂	Comorbidities	Cause of deaths
1	8	UC-MSC	173 mmHg—moderate	Hypertension, obesity	Multiorgan dysfunction syndrome
6	8	UC-MSC	175 mmHg—moderate	Diabetes, hypertension	Bacterial septic shock
8	20	UC-MSC	250 mmHg—mild	Hypertension	Bacterial septic shock
10	17	UC-MSC	180 mmHg—moderate	None	Bacterial septic shock
15	38	Placebo	99 mmHg—severe	Diabetes	Bacterial septic shock
17	23	UC-MSC	96 mmHg—severe	Diabetes, schizophrenia	Bacterial septic shock

PaO₂, arterial oxygen partial pressure; FiO₂, oxygen absorption concentration; UC-MSC, umbilical cord mesenchymal stromal cell

ISSN: 1757-6512